iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
146 hedge funds and large institutions have $704M invested in iTeos Therapeutics in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 45 reducing their positions, and 15 closing their positions.
120% more call options, than puts
Call options by funds: $1.01M | Put options by funds: $461K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
16% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 45
2% more funds holding
Funds holding: 143 → 146 (+3)
1% more capital invested
Capital invested by funds: $699M → $704M (+$4.97M)
1.4% less ownership
Funds ownership: 103.14% → 101.74% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$8.7M |
| 2 |
BlackRock
New York
|
+$3.17M |
| 3 |
6CM
683 Capital Management
New York
|
+$2.93M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.88M |
| 5 |
Millennium Management
New York
|
+$2.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$14.1M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$9.13M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.24M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.66M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.45M |
ITOS Hedge Fund Activity: Q4 2022 in Review
146 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q4 2022, worth a combined $704M — up 0.71% from $699M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ITOS positions and 15 closed out — a net gain of 4 holders — while 52 added to existing stakes and 45 trimmed.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $8.7M. The largest seller was Tang Capital Management, cutting an estimated $14.1M.
- 146 institutional investors held iTeos Therapeutics (ITOS) as of Q4 2022, up from 143 in Q3 2022.
- Funds reported $704M of iTeos Therapeutics stock for Q4 2022, up 0.71% quarter-over-quarter.
- 19 funds opened new iTeos Therapeutics positions in Q4 2022 and 15 closed out, a net change of +4 holders.
- The largest iTeos Therapeutics buyer in Q4 2022 was Octagon Capital Advisors, an estimated $8.7M added.
- The largest iTeos Therapeutics seller in Q4 2022 was Tang Capital Management, an estimated $14.1M sold.
Based on aggregated 13F filings for Q4 2022.